Treatment of Atopic Dermatitis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 30 December 2024 | Viewed by 531

Special Issue Editors


E-Mail Website
Guest Editor
Department of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Avenida de la Investigación s/n, 18016 Granada, Spain
Interests: atopic dermatitis; biological therapy; JAK inhibitors
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Dermatology Department, San Cecilio University Hospital, 18016 Granada, Spain
Interests: atopic dermatitis; topical treatment; systemic treatment; biological therapy; JAK inhibitors

Special Issue Information

Dear Colleagues,

Atopic dermatitis is a chronic inflammatory skin disease. Advances in the discovery of new therapeutic targets have facilitated the development of molecules with therapeutic potential. The reality is that there is a therapeutic paradigm shift in atopic dermatitis. It is necessary to stay updated in relation to the results observed in real clinical practice experience. It is also necessary to learn about new clinical trials and new potentially therapeutic molecules. Biological therapy promises new additions, such as nemolizumab or lebrikizumab. Currently, new JAK inhibitors are being studied, although no new ones appear to be incorporated in the near future. This Special Issue, titled Treatment of Atopic Dermatitis, will attempt to cover any potentially useful treatments in this disease.

Dr. Francisco José Navarro-Triviño
Dr. Ricardo Ruíz-Villaverde
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • eczema
  • topical treatment
  • systemic treatment
  • biological therapy
  • JAK inhibitor
  • antipruritic treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 1745 KiB  
Review
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
by Katarzyna Waligóra-Dziwak, Aleksandra Dańczak-Pazdrowska and Dorota Jenerowicz
J. Clin. Med. 2024, 13(14), 4001; https://doi.org/10.3390/jcm13144001 - 9 Jul 2024
Viewed by 368
Abstract
Atopic dermatitis (AD) is a skin condition characterized by significant challenges and a substantial deterioration in the life quality for affected patients. The therapeutic landscape for AD has witnessed a transformative shift with the emergence of biologic therapies. Our focus centers on biologics [...] Read more.
Atopic dermatitis (AD) is a skin condition characterized by significant challenges and a substantial deterioration in the life quality for affected patients. The therapeutic landscape for AD has witnessed a transformative shift with the emergence of biologic therapies. Our focus centers on biologics currently undergoing phase III and IV clinical trials, deeming them to hold the highest potential for significant clinical relevance. To identify biologic drugs under development in phase III and IV clinical trials, we searched ClinicalTrials.gov. Additional relevant trials were identified through JapicCTI/ Japan Registry of Clinical Trials (jRCT) with a citation search. A search in MEDLINE and EMBASE was performed. There have been 76 clinical trials identified concerning biologic drugs: dupilumab (34 trials), lebrikizumab (14 trials), tralokinumab (10 trials), rocatinlimab (7 trials), amlitelimab (2 trials), nemolizumab (6 trials), MG-K10 (1 trial), CM310 (1 trial), 611 (1 trial). A search in MEDLINE revealed 132 articles concerning phase III and IV clinical trials for AD treatment. A total of 39 articles concerned biologic drugs covering 23 clinical trials. A search in EMBASE revealed 268 relevant articles, allowing us to identify results of an additional six clinical trials. The safety and efficacy of these biologics are comprehensively addressed in this review. This comprehensive review aims to explore the current landscape of biologic therapies for AD, delving into the latest research findings, clinical trial outcomes, and the diverse mechanisms of action employed by these novel interventions. Full article
(This article belongs to the Special Issue Treatment of Atopic Dermatitis)
Show Figures

Figure 1

Back to TopTop